|
Name |
(3R,4aR,6aR,12bR)-3-(2-hydroxypropan-2-yl)-6a,12b-dimethyl-9-[(2S,4S)-4-methyl-3-oxohexan-2-yl]-1,2,3,4a,5,6,12,12a-octahydropyrano[3,2-a]xanthene-8,11-dione
|
Molecular Formula | C28H40O6 | |
IUPAC Name* |
(3R,4aR,6aR,12bR)-3-(2-hydroxypropan-2-yl)-6a,12b-dimethyl-9-[(2S,4S)-4-methyl-3-oxohexan-2-yl]-1,2,3,4a,5,6,12,12a-octahydropyrano[3,2-a]xanthene-8,11-dione
|
|
SMILES |
CC[C@H](C)C(=O)[C@@H](C)C1=CC(=O)C2=C(C1=O)O[C@@]3(CC[C@@H]4[C@@](C3C2)(CC[C@@H](O4)C(C)(C)O)C)C
|
|
InChI |
InChI=1S/C28H40O6/c1-8-15(2)23(30)16(3)17-13-19(29)18-14-20-27(6)11-9-21(26(4,5)32)33-22(27)10-12-28(20,7)34-25(18)24(17)31/h13,15-16,20-22,32H,8-12,14H2,1-7H3/t15-,16-,20?,21+,22+,27+,28+/m0/s1
|
|
InChIKey |
NTPNSKLZWVYKGK-DMBAJPFZSA-N
|
|
Synonyms |
COCHLIOQUINONE B
|
|
CAS | NA | |
PubChem CID | 139584864 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 472.6 | ALogp: | 3.9 |
HBD: | 1 | HBA: | 6 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 89.9 | Aromatic Rings: | 4 |
Heavy Atoms: | 34 | QED Weighted: | 0.568 |
Caco-2 Permeability: | -4.731 | MDCK Permeability: | 0.00002150 |
Pgp-inhibitor: | 0.88 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.221 |
30% Bioavailability (F30%): | 0.172 |
Blood-Brain-Barrier Penetration (BBB): | 0.239 | Plasma Protein Binding (PPB): | 99.51% |
Volume Distribution (VD): | 1.363 | Fu: | 1.68% |
CYP1A2-inhibitor: | 0.049 | CYP1A2-substrate: | 0.864 |
CYP2C19-inhibitor: | 0.106 | CYP2C19-substrate: | 0.691 |
CYP2C9-inhibitor: | 0.343 | CYP2C9-substrate: | 0.735 |
CYP2D6-inhibitor: | 0.448 | CYP2D6-substrate: | 0.219 |
CYP3A4-inhibitor: | 0.413 | CYP3A4-substrate: | 0.616 |
Clearance (CL): | 2.467 | Half-life (T1/2): | 0.375 |
hERG Blockers: | 0.051 | Human Hepatotoxicity (H-HT): | 0.616 |
Drug-inuced Liver Injury (DILI): | 0.031 | AMES Toxicity: | 0.011 |
Rat Oral Acute Toxicity: | 0.644 | Maximum Recommended Daily Dose: | 0.919 |
Skin Sensitization: | 0.733 | Carcinogencity: | 0.02 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.243 |
Respiratory Toxicity: | 0.195 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003007 | 0.786 | D0W5LS | 0.272 | ||||
ENC003011 | 0.784 | D04ATM | 0.260 | ||||
ENC002674 | 0.769 | D0F2AK | 0.254 | ||||
ENC004572 | 0.712 | D0Y7LD | 0.252 | ||||
ENC002182 | 0.712 | D01CKY | 0.250 | ||||
ENC005797 | 0.670 | D0Q4SD | 0.250 | ||||
ENC002924 | 0.614 | D0EP0C | 0.246 | ||||
ENC000943 | 0.600 | D0IX6I | 0.246 | ||||
ENC003006 | 0.586 | D0C7JF | 0.244 | ||||
ENC004573 | 0.580 | D02IQY | 0.243 |